ReviewInfection2026
30-day mortality and antifungal resistance in confirmed Candida auris bloodstream infections (BSI): a systematic review and meta-analysis.
Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida auris is a potentially multidrug-resistant nosocomial fungus that was classified as a WHO critical priority pathogen in 2022. Individual cohort studies report 30-day bloodstream infection mortality; however, prior meta-analyses have not restricted their primary pool to confirmed bloodstream infection cases.
methodsA PROSPERO-registered systematic review and meta-analysis was conducted (CRD420261418844). Studies enrolling patients with confirmed C. auris bloodstream infection and reporting 30-day or in-hospital all-cause mortality were included. Freeman-Tukey double arcsine transformation with DerSimonian-Laird random-effects modelling was applied to all proportion pools. Fluconazole and amphotericin B resistance were combined. Echinocandin resistance was synthesised narratively because of the zero-event problem. Subgroup analyses were pre-specified by geographic region and study designs.
resultsSixteen studies (N = 1,069 patients; 2016-2026) met the inclusion criteria. Pooled 30-day mortality from 13 studies (N = 813) was 39.6% (95% CI 32.4-47.0%; I
conclusionsConfirmed C. auris bloodstream infections have a pooled 30-day mortality rate of approximately 40%, along with near-universal fluconazole resistance. Echinocandins remain the first-line therapy, although mortality rates remain high. Susceptibility-guided therapy and enhanced infection control are essential.
Indexed as
Identifiers
42828623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.